First clinical trial using a galectin antagonist on SARS-CoV-2. Prolectin-M lowered viral protein levels to undetectable levels in 3 days (Mann Whitney U=0.000, p<0.029) This represents a novel way to block viral entry and replication. There were no SAE’s and participants were reactive with IgG within 28 days.